Cingulate has filed a prospectus supplement on August 19, 2024, to update its previous prospectus dated January 13, 2023. This new filing, made under Rule 424(b)(5) with Registration No. 333-269104, amends the amount of common stock Cingulate can offer and sell. The company is now eligible to sell shares with an aggregate offering price of up to $2,856,658 through H.C. Wainwright & Co., LLC, acting as the sales agent. This figure is in addition to the $8,468,402.99 worth of common stock already sold under the prior prospectus. The public float of Cingulate's common stock as of August 19, 2024, was valued at $28,709,843.98, based on the closing price of $17.69 per share on August 16, 2024. Over the past 12 months, the company has sold securities valued at $6,712,097.89. Cingulate's common stock is traded on the Nasdaq Capital Market under the ticker symbol 'CING'.

Cingulate has filed a prospectus supplement on August 19, 2024, to update its previous prospectus dated January 13, 2023. This new filing, made under Rule 424(b)(5) with Registration No. 333-269104, amends the amount of common stock Cingulate can offer and sell. The company is now eligible to sell shares with an aggregate offering price of up to $2,856,658 through H.C. Wainwright & Co., LLC, acting as the sales agent. This figure is in addition to the $8,468,402.99 worth of common stock already sold under the prior prospectus. The public float of Cingulate's common stock as of August 19, 2024, was valued at $28,709,843.98, based on the closing price of $17.69 per share on August 16, 2024. Over the past 12 months, the company has sold securities valued at $6,712,097.89. Cingulate's common stock is traded on the Nasdaq Capital Market under the ticker symbol 'CING'.